TPIDB > Outstanding PI
Outstanding PI
2025 Plastic Surgery
2025 Psychiatry
2025 Infectious Disease
2025 Nephrology
2025 Thoracic Surgery
2025 Thoracic Medicine
2025 Neurology
2025 Gastroenterological Surgery
2025 Digestive System
2025 Family Medicine
2025 Rheumatology
2025 Urology
2025 Hematology & Oncology
2025 Otolaryngology
2025 General Surgery
2025 Cardiovascular Surgery
2025 Cardiovascular Diseases
2025 Endocrinology
2025 Pediatrics
Highlights
Number of Clinical Trials 4
Phase 3 multicenter randomized clinical trials (MRCT) of ON101 demonstrated 60.7% vs 35.1% (p=0.0001) in complete healing rate in 16-week treatment. A subgroup analysis on difficult-to-heal ulcers also shows the stastistical significance, consistency, and robustness of the therapeutic effect of ON101. The related data was published in the international medical journal JAMA Network Open (JAMA Network Open.2021;4(9):e2122607)
